Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia
Abstract Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/30b5d2f52b594d5593705963e0ea8e51 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:30b5d2f52b594d5593705963e0ea8e51 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:30b5d2f52b594d5593705963e0ea8e512021-12-02T16:26:30ZClinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia10.1038/s41598-021-94438-42045-2322https://doaj.org/article/30b5d2f52b594d5593705963e0ea8e512021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94438-4https://doaj.org/toc/2045-2322Abstract Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated the utility of FLNA IP-MRM, age, and prostate volume to stratify men with BPH from those with PCa. Diagnostic performance of the biomarker panel was better than PSA alone in discriminating patients with negative biopsy from those with PCa, as well as those who have had multiple prior biopsies (AUC 0.75 and 0.87 compared to AUC of PSA alone 0.55 and 0.57 for patients who have had single compared to multiple negative biopsies, respectively). Of interest, in patients with PCa, the panel demonstrated improved performance than PSA alone in those with Gleason scores of 5–7 (AUC 0.76 vs. 0.56) and Gleason scores of 8–10 (AUC 0.74 vs. 0.47). With Gleason scores (8–10), the negative predictive value of the panel is 0.97, indicating potential to limit false negatives in aggressive cancers. Together, these data demonstrate the ability of the biomarker panel to perform better than PSA alone in men with BPH, thus preventing unnecessary biopsies.Michael A. KiebishPoornima TekumallaShobha RavipatyAlbert DobiShiv SrivastavaWenfang WuSaurabh PatilTracey FrissAllison KlotzAlagarsamy SrinivasanJennifer CullenInger L. RosnerAmina AliSandra LaszloMichele PetrovicNeil FleshnerJeonifer GarrenGreg MillerNischal Mahaveer ChandLeonardo O. RodriguesElder GrangerMark D. KelloggShen LuanEleftherios DiamandisViatcheslav R. AkmaevRangaprasad SarangarajanChas BountraStephen J. FreedlandDavid G. McLeodNiven R. NarainNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Michael A. Kiebish Poornima Tekumalla Shobha Ravipaty Albert Dobi Shiv Srivastava Wenfang Wu Saurabh Patil Tracey Friss Allison Klotz Alagarsamy Srinivasan Jennifer Cullen Inger L. Rosner Amina Ali Sandra Laszlo Michele Petrovic Neil Fleshner Jeonifer Garren Greg Miller Nischal Mahaveer Chand Leonardo O. Rodrigues Elder Granger Mark D. Kellogg Shen Luan Eleftherios Diamandis Viatcheslav R. Akmaev Rangaprasad Sarangarajan Chas Bountra Stephen J. Freedland David G. McLeod Niven R. Narain Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia |
| description |
Abstract Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated the utility of FLNA IP-MRM, age, and prostate volume to stratify men with BPH from those with PCa. Diagnostic performance of the biomarker panel was better than PSA alone in discriminating patients with negative biopsy from those with PCa, as well as those who have had multiple prior biopsies (AUC 0.75 and 0.87 compared to AUC of PSA alone 0.55 and 0.57 for patients who have had single compared to multiple negative biopsies, respectively). Of interest, in patients with PCa, the panel demonstrated improved performance than PSA alone in those with Gleason scores of 5–7 (AUC 0.76 vs. 0.56) and Gleason scores of 8–10 (AUC 0.74 vs. 0.47). With Gleason scores (8–10), the negative predictive value of the panel is 0.97, indicating potential to limit false negatives in aggressive cancers. Together, these data demonstrate the ability of the biomarker panel to perform better than PSA alone in men with BPH, thus preventing unnecessary biopsies. |
| format |
article |
| author |
Michael A. Kiebish Poornima Tekumalla Shobha Ravipaty Albert Dobi Shiv Srivastava Wenfang Wu Saurabh Patil Tracey Friss Allison Klotz Alagarsamy Srinivasan Jennifer Cullen Inger L. Rosner Amina Ali Sandra Laszlo Michele Petrovic Neil Fleshner Jeonifer Garren Greg Miller Nischal Mahaveer Chand Leonardo O. Rodrigues Elder Granger Mark D. Kellogg Shen Luan Eleftherios Diamandis Viatcheslav R. Akmaev Rangaprasad Sarangarajan Chas Bountra Stephen J. Freedland David G. McLeod Niven R. Narain |
| author_facet |
Michael A. Kiebish Poornima Tekumalla Shobha Ravipaty Albert Dobi Shiv Srivastava Wenfang Wu Saurabh Patil Tracey Friss Allison Klotz Alagarsamy Srinivasan Jennifer Cullen Inger L. Rosner Amina Ali Sandra Laszlo Michele Petrovic Neil Fleshner Jeonifer Garren Greg Miller Nischal Mahaveer Chand Leonardo O. Rodrigues Elder Granger Mark D. Kellogg Shen Luan Eleftherios Diamandis Viatcheslav R. Akmaev Rangaprasad Sarangarajan Chas Bountra Stephen J. Freedland David G. McLeod Niven R. Narain |
| author_sort |
Michael A. Kiebish |
| title |
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia |
| title_short |
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia |
| title_full |
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia |
| title_fullStr |
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia |
| title_full_unstemmed |
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia |
| title_sort |
clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/30b5d2f52b594d5593705963e0ea8e51 |
| work_keys_str_mv |
AT michaelakiebish clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT poornimatekumalla clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT shobharavipaty clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT albertdobi clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT shivsrivastava clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT wenfangwu clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT saurabhpatil clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT traceyfriss clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT allisonklotz clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT alagarsamysrinivasan clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT jennifercullen clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT ingerlrosner clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT aminaali clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT sandralaszlo clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT michelepetrovic clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT neilfleshner clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT jeonifergarren clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT gregmiller clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT nischalmahaveerchand clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT leonardoorodrigues clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT eldergranger clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT markdkellogg clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT shenluan clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT eleftheriosdiamandis clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT viatcheslavrakmaev clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT rangaprasadsarangarajan clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT chasbountra clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT stephenjfreedland clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT davidgmcleod clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia AT nivenrnarain clinicalutilityofaserumbiomarkerpanelindistinguishingprostatecancerfrombenignprostatehyperplasia |
| _version_ |
1718384042956554240 |